Pfizer's "Delete! Delete!" memo: "Do NOT forward or retain this e-mail . . ."
Jane Roe, Pfizer's maraviroc whistleblower has provided a very unusual memo from Pfizer, see below. (For background click here.)
Jane says "The promoting of unapproved or off label material even to the sales reps is strictly forbidden. All training materials for training or distibution are to be regulatory approved. Arthur has sent out a directive for us to delete this information because it was unapproved even though he and the medical liaisons freely distributed it to us."
From: Rodriguez, Arthur (Agouron)
Sent: Thursday, January 04, 2007 2:46 PM
To: Binion, Russell A; Jones, Jackie E; Kerns, Jacqueline M; Krall, Jody; Lee, Jim; Mlambo, Debra; Pulliam, Wayne Anthony; Rascoe, Sharon Y; Smiley, Tracy; Traylor, Rhoyge W; Fitzgerald, Kelly; McCarty, Gene; Mumford, Robert E; Vollmers, Thomas L; Yost, John (La Jolla); Zaleski, Carolyn; Brake, Jeffrey; Ceperley, Mark A; Ebenroth, Joseph; Ferguson, Bettye J; Hopkins, Melanie E; Jaconetta, James; Miller, Adam M; Rossbach, Mareen; Seaver, David S; Snyder, Elizabeth L; Adcock, Bryan; Bestler, Michael; Cragar, John B; DeRamus, Lisa A; Evans, Jay; Fazzina, Douglas; Frank, Denise; Glazer, Bruce J; Grice, Karen; Jackson, Kyle A; Larralde, Mark; Lovelady, Johnny F; McCauley, Nancy; Pieper, Shasta; Raymond, James; Root, Tamara; Shimp, Christine Lynn; Snody, Bonnie J; Soler, Jennifer D; Staver, Kent; Stephenson, Kimberly A; Stinson, Kelly N; Tabraue, Alex; Taylor, Joan; Turner, Edward; Weiss, Lawrence; Williams, Brennetta C; Woll, Joyce M
Subject: Confidential: MARAVIROC Update - CCR5/Disease State Education
In an effort to keep the field informed of ongoing activities regarding MVC, please be aware of the following campaign which will initiate this month. This is for your information only. Please do not proactively discuss this with your physicians and customers. All educational materials and information will be the sole responsibility of the U.S. marketing team. Our response, if brought up by one of our customers, must be limited to acknowledgement of the program only.
Please Do NOT forward or retain this e-mail. FYI only. Do NOT Detail or discuss with Customers.
Pfizer HIV/AIDS Division
National Sales Office
18500 Von Karman, Suite 600
Irvine, CA 92612
Office: (949) 794-1505
FAX: (949) 794-1509
Voice mail: 81945
Cell: (760) 473-1807
Clearly, Mr. Art "Delete! Delete!" Rodriguez doesn't realize that about the most stupid thing any corporate manager can do is to send an e-mail to over fifty co-workers and expect that if he writes "Please Do NOT forward or retain this e-mail" they will actually delete that e-mail and not forward it to all their friends, laughing.
He also doesn't seem to understand that to write such a memo is pretty close to corporate suicide, since only a person who THINKS he has something to hide goes on the record ordering document destruction of the e-mail he just wrote . . .
The revelation of this memo comes on the heels of another Pfizer HIV/AIDS division memo from Pfizer Vice President Mark Brown, in which he wrote "First, because Maraviroc has not been approved by the FDA, you must not engage in any form of pre-approval promotion . . . you must advise the questioner that you are not able to respond to the question in light of the pending regulatory application . . . The consequences of pre-approval promotion can be significant, and can go beyond disciplinary action for violation of a Company Policy . . . Any promotional conduct at this point in time could adversely influence the FDA’s views on either the label or the Risk Plan, could prompt the FDA to send Pfizer a Regulatory letter or could lead to other legal action."
The only problem with THAT memo was that Mark "I told 'em not to do it!" Brown, sent his memo several days AFTER this blog had revealed allegations of illegal premarketing by Pfizer's HIV/AIDS sales force; allegations that were confirmed yesterday in numerous internal Pfizer e-mails republished in my article "Pfizer sales rep: 'PFE tried to find 'naïve doctors' for illegal premarketing of maraviroc!'"
For the entire maraviroc story, click here.